Positive results with lenvatinib for the treatment of advanced medullary thyroid cancer in a phase II trial

被引：0
|
作者：
机构：
来源：
Nature Reviews Endocrinology | 2015年 / 11卷 / 11期
关键词：
D O I：
10.1038/nrendo.2015.157
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：632 / 632
相关论文
共 50 条
  • [31] Phase II trial of sorafenib in patients with advanced thyroid cancer.
    Keefe, S. M.
    Troxel, A. B.
    Rhee, S.
    Puttaswamy, K.
    O'Dwyer, P. J.
    Loevner, L. A.
    Mandel, S. J.
    Brose, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
    Chen, Jiaying
    Ji, Qinghai
    Cao, Junning
    Ji, Dongmei
    Bai, Chunmei
    Lin, Yansong
    Pan, Bin
    Sun, Guofang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
    Wirth, Lori J.
    Brose, Marcia S.
    Sherman, Eric J.
    Licitra, Lisa
    Schlumberger, Martin
    Sherman, Steven, I
    Bible, Keith C.
    Robinson, Bruce
    Rodien, Patrice
    Godbert, Yann
    De La Fouchardiere, Christelle
    Newbold, Kate
    Nutting, Christopher
    Misir, Soamnauth
    Xie, Ran
    Almonte, Ana
    Ye, Weifei
    Cabanillas, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2359 - +
  • [34] Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
    Keam, B.
    Hu, M. I.
    Subbiah, V.
    Wirth, L.
    Schuler, M.
    Mansfield, A. S.
    Brose, M. S.
    Curigliano, G.
    Leboulleux, S.
    Zhu, V. W.
    Matos, I.
    Adkins, D.
    Baik, C. S.
    Lopes, G.
    Godbert, Y.
    Sarker, D.
    Zhang, H.
    Turner, C. D.
    Taylor, M. H.
    Lin, C-C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1413 - S1414
  • [35] Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
    Hu, M.
    Subbiah, V.
    Wirth, L. J.
    Schuler, M.
    Mansfield, A. S.
    Brose, M. S.
    Curigliano, G.
    Leboulleux, S.
    Zhu, V. W.
    Keam, B.
    Matos, I.
    Lin, C-C.
    Adkins, D.
    Baik, C. S.
    Lopes, G.
    Godbert, Y.
    Sarker, D.
    Zhang, H.
    Turner, C.
    Taylor, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1084 - S1084
  • [36] Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC)
    Cabanillas, M. E.
    Kurzrock, R.
    Sherman, S. I.
    Tsimberidou, A. M.
    Waguespack, S.
    Naing, A.
    Busaidy, N.
    Gagel, R.
    Wright, J. J.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] COMBINATION CHEMOTHERAPY OF ADVANCED MEDULLARY AND DIFFERENTIATED THYROID-CANCER - PHASE-II STUDY
    SCHERUBL, H
    RAUE, F
    ZIEGLER, R
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (01) : 21 - 23
  • [38] Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial
    Wells, S. A., Jr.
    Gosnell, J. E.
    Gagel, R. F.
    Moley, J. F.
    Pfister, D. G.
    Sosa, J. A.
    Skinner, M.
    Krebs, A.
    Hou, J.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma
    Dierks, C.
    Ruf, J.
    Seufert, J.
    Kreissl, M.
    Klein, C.
    Spitzweg, C.
    Kroiss, M.
    Thomusch, O.
    Lorenz, K.
    Zielke, A.
    Miething, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1295 - S1295
  • [40] Phase II trial of sorafenib in advanced thyroid cancer: A disease site analysis
    Cohen, Aaron Benjamin
    Yarchoan, Mark
    Troxel, Andrea B.
    Puttaswamy, Kanchan
    Harlacker, Kathleen
    Loevner, Laurie A.
    Brose, Marcia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345